Advertisement

International Journal of Hematology

, Volume 107, Issue 6, pp 656–665 | Cite as

Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan

  • Yasutaka Ueda
  • Naoshi Obara
  • Yuji Yonemura
  • Hideyoshi Noji
  • Masayoshi Masuko
  • Yoshinobu Seki
  • Katsuya Wada
  • Takahisa Matsuda
  • Hirozumi Akiyama
  • Takayuki Ikezoe
  • Shigeru Chiba
  • Yoshinobu Kanda
  • Tatsuya Kawaguchi
  • Tsutomu Shichishima
  • Hideki Nakakuma
  • Shinichiro Okamoto
  • Jun-ichi Nishimura
  • Yuzuru Kanakura
  • Haruhiko Ninomiya
Original Article
  • 551 Downloads

Abstract

In paroxysmal nocturnal hemoglobinuria (PNH), various symptoms due to intravascular hemolysis exert a negative impact on patients’ quality of life (QOL). To determine clinical factors related with improvements in QOL in PNH patients treated, we analyzed changes in QOL scales in PNH patients treated with eculizumab based on data collected from post-marketing surveillance in Japan. Summary statistics were obtained using figures from QOL scoring systems and laboratory values, and evaluated by t test. One-year administration of eculizumab improved the most QOL items in comparison with the baseline. In particular, significant improvement of EORTC QLQ-C30 was observed in fatigue, dyspnea, physical function, and global health status. Canonical correlation analysis revealed a high correlation between QOL and laboratory values. Changes in serum lactate dehydrogenase (LDH) and hemoglobin showed strong correlations with QOL improvement. Quality of life improvement was independent of patients’ baseline characteristics of co-occurrence of bone marrow failure (BMF), or the degree of LDH. In this analysis, we found that the degree of QOL improvement was independent of the baseline LDH before eculizumab treatment and of co-occurrence of BMF. Paroxysmal nocturnal hemoglobinuria patients who have not received eculizumab treatment due to mild hemolysis may benefit from eculizumab treatment.

Keywords

PNH QOL Patient-reported outcome Complement inhibitor Eculizumab 

Notes

Acknowledgements

We thank all participating physicians and registered patients who took part in this surveillance study. We are grateful to Dr. Yasuo Ohashi of Dep. Integrated Science and Engineering for Sustainable Society, Chuo University for special advice on research design including statistical analysis. This study was sponsored by Alexion, and Alexion was involved in the process of the study design, data collection, analysis and manuscript preparation. Alexion approved the content of the manuscript and the submission of the manuscript for publication.

Funding

Logistical and financial cost for the post-marketing surveillance of eculizumab including statistical analysis was provided by Alexion Pharma GK.

Compliance with ethical standards

Conflict of interest

Dr. Kawaguchi reported personal fees from Alexion Pharma G.K., outside the submitted work; Dr. Ueda reported personal fees from Kyowa Hakko Kirin Co.Ltd. and from Celgene, outside the submitted work; Dr. Shichishima and Dr. Yonemura, report grants from Alexion Pharma G.K., outside the submitted work; Dr. Ueda, Dr. Nishimmura, Dr. Ninomiya report grant and personal fees from Alexion Pharma G.K., during the conduct of the study; Dr. Chiba report grand from Alexion Pharma G.K., during the conduct of the study. Dr. Okamoto reports grants from Alexion Pharma G.K. and from Chugai Pharmaceutical Co. Ltd., outside the submitted work. Dr. Kanakura reports grants from Alexion Pharma G.K. and from Chugai Pharmaceutical Co. Ltd. Dr. Obara, Dr. Seki, Dr. Kanda, Dr. Nakakuma, Dr. Ikezoe, and Dr. Masuko, Dr. Noji and Dr. Wada have nothing to declare; Dr. Matsuda and Mr. Akiyama report other from Alexion Pharma G.K., outside the submitted work; Employee of Alexion Pharma G.K. and Stock/stock options in the company.

References

  1. 1.
    Miyata T, Yamada N, Iida Y, Nishimura J, Takeda J, Kitani T, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994;330:249–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–709.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99:922–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Almeida AM, Bedrosian C, Cole A, Muus P, Schrezenmeier H, Szer J, et al. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Intern Med J. 2017;47:1026–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Brodsky RA, Young NS, Antonoli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93:36–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol. 2013;98:406–16.CrossRefPubMedGoogle Scholar
  10. 10.
    Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104:548–58.CrossRefPubMedGoogle Scholar
  11. 11.
    Cella D. Manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Evanston IL, Version 4. 1997.Google Scholar
  12. 12.
    Yoshimura A, Kobayashi K, Fumimoto H, Fujiki Y, Eremenco S, Kudoh S. Cross-cultural validation of the Japanese functional assessment of cancer therapy-anemia (FACT-An). J Nippon Med Sch. 2004;71:314–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.Google Scholar
  14. 14.
    Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S, et al. A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer. 1998;34:810–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24:547–61.CrossRefPubMedGoogle Scholar
  16. 16.
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Groth M, Singer S, Niedeggen C, Petermann-Meyer A, Röth A, Schrezenmeier H, et al. Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. Ann Hematol. 2017;96:171–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Weitz I, Meyers G, Lamy T, Cahn JY, Uranga MT, García Vela JA, et al. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Int Med J. 2013;43:298–307.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Yasutaka Ueda
    • 1
    • 2
  • Naoshi Obara
    • 2
    • 3
  • Yuji Yonemura
    • 2
    • 4
  • Hideyoshi Noji
    • 2
    • 5
  • Masayoshi Masuko
    • 6
  • Yoshinobu Seki
    • 7
    • 8
  • Katsuya Wada
    • 9
  • Takahisa Matsuda
    • 10
  • Hirozumi Akiyama
    • 10
  • Takayuki Ikezoe
    • 2
    • 5
  • Shigeru Chiba
    • 2
    • 11
  • Yoshinobu Kanda
    • 2
    • 12
  • Tatsuya Kawaguchi
    • 2
    • 13
  • Tsutomu Shichishima
    • 2
    • 5
  • Hideki Nakakuma
    • 2
    • 14
  • Shinichiro Okamoto
    • 2
    • 15
  • Jun-ichi Nishimura
    • 1
    • 2
  • Yuzuru Kanakura
    • 1
    • 2
  • Haruhiko Ninomiya
    • 2
    • 16
  1. 1.Department of Hematology and OncologyOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Japan PNH Study GroupTokyoJapan
  3. 3.Department of HematologyUniversity of TsukubaTsukubaJapan
  4. 4.Department of Transfusion Medicine and Cell TherapyKumamoto University HospitalKumamotoJapan
  5. 5.Department of HematologyFukushima Medical UniversityFukushimaJapan
  6. 6.Department of Stem Cell TransplantationNiigata University HospitalNiigataJapan
  7. 7.Department of HematologyNiigata Prefectural Shibata HospitalShibataJapan
  8. 8.Department of Hematology, Uonuma Institute of Community MedicineNiigata University Medical and Dental HospitalMinami-UonumaJapan
  9. 9.Department of HematologyMatsushita Memorial HospitalMoriguchiJapan
  10. 10.Alexion Pharma G.KTokyoJapan
  11. 11.Department of Hematology, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  12. 12.Division of HematologyJichi Medical UniversityShimotsukeJapan
  13. 13.Departments of Hematology and Infectious DiseasesKumamoto UniversityKumamotoJapan
  14. 14.Kagoshima Tokusyukai HospitalKagoshimaJapan
  15. 15.Division of Hematology, Department of MedicineKeio University School of MedicineTokyoJapan
  16. 16.Department of Medical Sciences, Faculty of MedicineUniversity of TsukubaTsukubaJapan

Personalised recommendations